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Abstract
The pivotal role of KCC2 and NKCC1 in development and maintenance of fast inhibitory
neurotransmission and their implication in severe human diseases arouse interest in post-
transcriptional regulatory mechanisms such as (de)phosphorylation. Staurosporine (broad
kinase inhibitor) and N-ethylmalemide (NEM) that modulate kinase and phosphatase activi-
ties enhance KCC2 and decrease NKCC1 activity. Here, we investigated the regulatory
mechanism for this reciprocal regulation by mass spectrometry and immunoblot analyses
using phospho-specific antibodies. Our analyses revealed that application of staurosporine
or NEM dephosphorylates Thr1007 of KCC2, and Thr203, Thr207 and Thr212 of NKCC1.
Dephosphorylation of Thr1007 of KCC2, and Thr207 and Thr212 of NKCC1 were previously
demonstrated to activate KCC2 and to inactivate NKCC1. In addition, application of the two
agents resulted in dephosphorylation of the T-loop and S-loop phosphorylation sites Thr233
and Ser373 of SPAK, a critical kinase in the WNK-SPAK/OSR1 signaling module mediating
phosphorylation of KCC2 and NKCC1. Taken together, these results suggest that reciprocal
regulation of KCC2 and NKCC1 via staurosporine and NEM is based on WNK-SPAK/OSR1
signaling. The key regulatory phospho-site Ser940 of KCC2 is not critically involved in the
enhanced activation of KCC2 upon staurosporine and NEM treatment, as both agents have
opposite effects on its phosphorylation status. Finally, NEM acts in a tissue-specific manner
on Ser940, as shown by comparative analysis in HEK293 cells and immature cultured hippo-
campal neurons. In summary, our analyses identified phospho-sites that are responsive to
staurosporine or NEM application. This provides important information towards a better
understanding of the cooperative interactions of different phospho-sites.
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Introduction
The cation chloride cotransporter family (CCCs) consists of electroneutral secondary active
cotransporters that mediate the symport of cations (Na+ and K+) coupled with chloride ions
(Cl-) across the plasma membrane. CCCs are divided into K+-Cl- outward cotransporters
(KCC1-4), Na+, K+, Cl- inward cotransporters (NKCC1-2, NCCs), the polyamine transporter
CCC9, and the CCC-interacting protein CIP1 [1–3]. These transporters play a crucial role in
various physiological processes like regulation of cell volume, directional ion transport across
epithelial cells, secretion of K+, and regulation of intracellular Cl−concentration ([Cl-]i) in neu-
rons [2, 4–11].
In neurons, KCC2 and NKCC1 are involved in the development and maintenance of
inhibitory neurotransmission. For instance, KCC2 generates a low [Cl-]i required for fast
inhibitory neurotransmission. Binding of γ-aminobutyric acid (GABA) or glycine to their
receptors, which are ligand-gated Cl- channels, leads to a Cl- influx and therefore hyperpo-
larization [8, 12]. By contrast, NKCC1 is more prevalent in immature inhibitory neurons.
There, its action results in a high [Cl-]i causing GABA or glycine to elicit a depolarizing
action that opens L-type voltage-gated Ca2+ channels necessary for proper synapse forma-
tion [13–18].
The physiological relevance of the two cotransporters is corroborated by the phenotypes
present in knockout mice. Mice with disruption of the gene Slc12a5 encoding both KCC2 iso-
forms (KCC2a and KCC2b), die shortly after birth due to motor deficits [19, 20]. Furthermore,
dysfunction of KCC2 is associated with neurological and psychiatric disorders including epi-
lepsy, neuropathic pain, spasticity, ischemic insults, brain trauma, schizophrenia, and autism
[21–32]. Mice with disruption of Slc12a2 (NKCC1) are viable, but suffer from peripheral deaf-
ness, postnatal hyperexcitability and anti-convulsant, pain perception and male infertility [33–
36]. Inhibition of KCC2 promotes formation of pathological conditions whereas inhibition of
NKCC1 seems to prevent or at least alleviate pathological phenotypes [37]. This renders these
two transporters a prime pharmacotherapeutic target and fosters interest in understanding
posttranslational mechanisms of their regulation [12, 38–40]. The main focus is set on phos-
pho-related mechanisms. The broad kinase inhibitor staurosporine was used to enhance
KCC2 transport activity in immature auditory brainstem [41] and hippocampal cultured neu-
rons [42], and to decrease NKCC1 activity [43–46]. Furthermore, N-ethylmaleimide (NEM),
that likely modulates the activity of kinases and phosphatases, activates KCC2 [47–50] and
inhibits NKCC1 [45, 51]. Thus, both compounds reciprocally regulate KCC2 (activation) and
NKCC1 (inhibition). Understanding their mode of action provides the basis for further phar-
macological studies and important insight into the molecular mechanisms involved in physio-
logical regulation of these two transporters.
Since KCC2 and NKCC1 are present in the same neuronal populations but transport K+
and Cl- in opposite direction [52–54], regulatory mechanisms are required to coordinate their
activity [4, 38, 55–60]. Indeed, several kinases and phosphatases regulate their transport activ-
ity. In vitro and in vivo analyses revealed that members of the with-no-lysine kinase (WNKs)
family in combination with their downstream targets STE20/SPS1-related proline/alanine rich
kinase (SPAK) and oxidative stress response kinase (OSR1) are the most prominent kinases
that regulate KCC2 and NKCC1 activity in a reciprocal way. SPAK/OSR1, activated by
WNK1, phosphorylate Thr6 and Thr1007 of KCC2 [48, 59, 61–64]. WNKs also interact with a
yet unknown kinase to phosphorylate Thr906 of KCC2 [48, 63]. Site-directed mutagenesis stud-
ies indicate that simultaneous mutation of Thr906 and Thr1007 to alanine (mimicking the
dephosphorylated state) activates KCC2 [61, 65–67]. WNK/SPAK/OSR1 also phosphorylates
the N-terminal residues Thr203, Thr207, Thr212 and Thr217 of NKCC1 [38, 59, 60, 68–76]
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thereby activating NKCC1 [72, 75]. Thus dephosphorylation (KCC2) and phosphorylation
(NKCC1) of WNK/SPAK/OSR1 specific phospho-sites enhance KCC2 and NKCC1 activity.
Phosphorylation can also enhance KCC2 activity. Phosphorylation of Ser932, Thr934, Ser937,
or the protein kinase C (PKC) site Ser940, all residing in exon 22, increases its transport activity
[47, 68, 77]. The multiplicity of phosphorylation/dephosphorylation sites on KCC2 offers a
complex toolbox to gradually fine-regulate its activity and integrate different signaling path-
ways [4, 40, 65, 68].
Initially, both staurosporine and NEM were thought to act through a similar mechanism
[47], but recent findings revealed that they act differentially on specific KCC2 phospho-sites
[40]. Furthermore, staurosporine and NEM mediated effects involve both KCC2 phosphoryla-
tion and dephosphorylation [40, 48]. To gain insight into their mode of action, we analyzed
the impact of these compounds on phosphorylation of specific KCC2 and NKCC1 phospho-
sites using large-scale phosphoproteomics studies and phospho-site specific antibodies in sta-
bly transfected HEK293 cells and immature primary cultures of hippocampal neurons.
Material and methods
Cell culturing of HEK293 cells
For K+-Cl- cotransporter activity measurements, stably transfected rat KCC2b HEK293 cells
(HEKrnKCC2b) [55] were plated in a 0.1 mg/ml poly-L-lysine coated black-well 96 well culture
dish (Greiner Bio-One, Frickenhausen, Germany) at a concentration of 100,000 cells/well. The
remaining cells were plated on a 0.1 mg/ml poly-L-lysine-coated class coverslip and ~18 h later
analyzed by immunocytochemistry.
Primary cultures of rat hippocampal neuron
All animal procedures were carried out in accordance with the European Union Directive of
22 September (2010/63/EU). The protocol was approved by the INSERM Local committee
(Number 0287.01, delivered by Ministère de l’Education et de la Recherche). Hippocampi
from 18-day-old rat embryos were dissected and dissociated using trypsin (0.05%) and plated
in 60-mm culture dishes at a density of 100,000 cells cm−2 in minimal essential medium
(MEM) supplemented with 10% NU serum (BD Biosciences, Le Pont de Claix, France), 10
mM glucose, 1 mM sodium pyruvate, 2 mM glutamine, and 100 U ml−1 penicillin–streptomy-
cin as previously described [78]. On day 7 of culture incubation, half of the medium was
changed to MEM with 2% B27 supplement (Invitrogen). 24 h prior to plating, dishes were
coated with poly-ethylenimine (5 μg/ml).
Immunocytochemistry
For immunocytochemistry, all steps were performed at room temperature. HEK293 cells
grown on poly-L-lysine-coated coverslips were fixated for 10 min with 4% paraformaldehyde
in 0.2 M phosphate buffer (PBS). After three washing steps in PBS, cells were incubated with
blocking solution (2% bovine serum albumin, 10% goat serum in PBS) for 30 min. Primary
antibody solution (anti-KCC2 N1-12; 1:1,000; Neuromab, Carlifornia, USA) was added in car-
rier solution (0.3% Triton X-100, 1% bovine serum albumin, 1% goat serum in PBS) for 1 h.
After washing three times in PBS, the secondary antibody, which was conjugated to a fluores-
cent probe (Alexa Fluor 488 goat anti-mouse; 1:1,000; Thermo Fisher Scientific, Bremen, Ger-
many) was incubated for 1 h. After three washes in PBS, cells were mounted onto glass slides
with Mowiol (Roth, Karlsruhe, Germany) and DAPI (Roth; 1:1,000). Photomicrographs were
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taken using Biozero BZ-8100E (Keyence, Neu-Isenburg Deutschland) fluorescence micro-
scope (Leica, Wetzlar, Germany).
Determination of K+-Cl- cotransport
KCC2 transport activity was determined by Cl−dependent uptake of Tl+ in HEK293 cells as
previously described [47, 79, 80]. To initiate the flux measurement, the medium in the 96-well
culture dish was replaced by 80 μl preincubation buffer (100 mM N-methyl-D-glucamine-
chloride, 5 mM HEPES, 5 mM KCl, 2 mM CaCl2, 0.8 mM MgSO4, 5 mM glucose, pH 7.4, 160
mmol / kg ± 2,04 mmol/kg) supplemented with 2 μM FlouZin-2 AM dye (Thermo Scientific,
Bremen, Germany) plus 0.2% (wt/vol) Pluronic F-127 (Thermo Scientific, Bremen, Germany)
and incubated for 48 min at room temperature. Cells were then washed 3 times with 80 μl pre-
incubation buffer and incubated for 15 min with 80 μl preincubation buffer plus 0.1 mM oua-
bain to block Na+/K+ ATPase activity. Three technical and five biological replicates were
performed for each construct. Afterwards, the 96-well plate was placed into a fluorometer
(Fluoroskan Accent, Thermo Scientific, Bremen, Germany) and each well was injected with
40 μl 5 x Tl+ stimulation buffer (12 mM Tl2SO4, 100 mM NMDG, 5 mM Hepes, 2 mM KCl, 2
mM CaCl2, 0.8 mM MgSO4, 5 mM glucose, pH 7.4; 175 mmol/kg ± 2 mmol/kg). Fluorescence
was determined in a kinetic dependent manner (excitation 485 nm, emission 538 nm, 1 frame
in 5 s in a 200 s time span) across the entire cell population in a single well. By using linear
regression of the initial values of the slope of Tl+-stimulated fluorescence increase, transport
activity was calculated [79, 80].
To determine the dose-response profile, increasing concentration of staurosporine (8–
80 μM) and NEM (25–3000 μM) were applied to the preincubation buffer 15 min prior flux
measurement. This was done for three technical replicates and at least five independent mea-
surements were performed.
Statistical analyses
The majority of data populations illustrated in Figs 1, 3 and 4 showed non-normal distribu-
tions (verified using Shapiro-Wilk normality test at 0.05 significance level). Therefore, a non-
parametric test (Wilcoxon-Mann-Whitney rank sum test) was employed for the comparison
between different groups of data. The resulting p-values were adjusted with the Bonferroni
correction for multiple testing. Note that only p-values < 0.01 were considered to reduce the
chances of false positives (type I errors). The sample size n always refers to the number of bio-
logical replicates (independent preparations). The activity of each independent preparation
was determined as mean over three technical replicates. The average scatter within technical
replicates was 3 times smaller than the scatter across biological replicates for a given treatment.
For dose-response analyses, we used the nls function from the stats package in R (version
3.5.1) to model the data points with the Hill-Langmuir equation,
y x; ED50; n; ysatð Þ ¼ y0 þ ysat
xn
ED50
n þ xn
; ð1Þ
where y is the Tl+ uptake of HEKrnKCC2b cells, y0 is the Tl+ independent-baseline activity (y0 =
100%), ysat is the maximum activity (equivalent to Vmax in reaction rate equation) relative to
baseline, x is the concentration of the agonist, n is the Hill coefficient, and ED50 is the agonist
concentration that produces 50% of the saturation response. The 95% confidence intervals for
the dose response curves were determined with the function NonlinearModelFit [“MeanPre-
dictionBands”] in Wolfram Mathematica. For the boxplots, the box extends from the upper
(Q1) to the lower (Q3) quartile. The line inside the box represents the median. The whiskers
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extend to the outermost data point that falls within upper inner and lower inner Quartile
fences [Q1+1.5(IQR)] and [Q3-1.5(IQR)], respectively, where IQR = Q1-Q3 is the interquar-
tile range.
Treatment of stably transfected HEKrnKCC2b cells and hippocampal
neurons
For mass spectrometry and immunoblot analyses, stably transfected HEKrnKCC2b cells [55]
were grown in 75 cm2 cell-culture flask. Cells were washed with 5 ml flux hypotonic preincu-
bation buffer (100 mM N-methyl-D-glucamine-chloride, 5 mM HEPES, 5 mM KCl, 2 mM
CaCl2, 0.8 mM MgSO4, 5 mM glucose, pH 7.4; 160 mmol/kg±2,04 mmol/kg) and then treated
with or without 8 μM staurosporine or 1 mM NEM. Cells were centrifuged at 500 rpm for 3
min and the resulting pellets used for immunoblot analyses or mass spectrometry analyses.
For immunoblot analyses of immature (9 days in vitro, (DIV)) rat hippocampal neurons,
half of the media from culture dishes containing neurons (2.5 ml from each dish) was collected
to prepare samples including 16 μM staurosporine (from 10 mM stock solution in DMSO), 1
mM NEM (by direct dissolving of the NEM powder) or DMSO (vehicle, same volume as for
staurosporine), respectively. The samples were distributed dropwise into the culture dishes
that gave final concentration of 8 μM staurosporine or 0.5 mM NEM and cultures were incu-
bated 15 min at 37 ˚C (5% CO2). After incubation, neurons were rinsed twice with Hanks’ Bal-
anced Salt solution (HBSS, ThermoFisher Scientific) precooled to 4 ˚C. The rinsage solution
was replaced with ice-cold HBSS containing a cocktail of protease and phosphatase inhibitors
(ThermoFisher Scientific) and neurons rapidly scraped and centrifuged at 4 ˚C (10,000 g, 3
min). Pellets were frozen in liquid nitrogen and kept for future analyses at -80 ˚C.
Multi-Enzyme Digestion Filter Aided Sample preparation (MED FAS)
For mass spectrometry analyses, cell pellets of untreated, staurosporine or NEM treated
HEKrnKCC2b cells were lysed in 2% SDS in 0.1 M Tris-HCl, pH 8.0, containing 0.1 M DTT as
described previously [81]. Total protein was determined using WF-assay in micro-titer plate
format [82]. Aliquots of the cell lysate containing 1–2 mg were processed in Amicon Ultra 15
Ultracel 30k (Merck Millipore, Darmstadt) devices as described previously [83] with several
modifications using the MED FASP method [84]. Briefly, SDS and other low molecular weight
material were removed by centrifugation at 4,000 x g in 5 consecutive washes with UA buffer
containing 8 M urea (ultrapure, Merck, Darmstadt) in 0.1 M Tris pH 8. Following two washes
with 5 ml of 0.1M Tris-HCl, pH 8 (DB buffer), 20 μg of LysC (Wako, Neuss) in 0.5 mL of DB
was added to the filter. Samples were digested overnight at 37 ˚C and peptides were collected
by centrifugation. Next, the material retained in the filter was cleaved with 10 μg trypsin in 0.5
ml DB at 37 ˚C for 4 h and the peptides were eluted as previously. To increase the yield of pep-
tides, filters were washed twice with 0.5 mL DB. Concentration of peptides was determined by
WF-assay [82].
TiO2-based enrichment of phosphopeptides
Phosphopeptides were enriched using TiO2-beads [85] with several modifications [83]. Briefly,
25 mg of ‘Titansphere TiO2 10 μm’ (GL Sciences, Inc., Japan) were suspended in 50 μl of 3%
(m/v) dihydroxybenzoic acid in 80% (v/v) CH3CN, 0.1% CF3COOH and diluted 1:4 with
water before use. Ten microliters of this slurry (1 mg beads) were added and samples incu-
bated under continuous agitation for 20 min. The mass ratio of the beads and peptides was 3:1.
Then, the titanium beads were sedimented by centrifugation at 5,000 x g for 1 min and the
supernatants were collected and mixed with another portion of the beads and incubated as
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above. The bead-pellets were resuspended in 150 μl of 30% (v/v) CH3CN containing 3% (v/v)
CF3COOH and transferred to a 200 μl pipet tip plugged with one layer of glass microfiber filter
GFA (Whatman). The beads were washed three times with 30% (v/v) CH3CN, 3% CF3COOH
(v/v) solution and three times with 80% CH3CN (v/v), 0.3% CF3COOH (v/v) solution. Finally,
the peptides were eluted from the beads with 100 μL of 40% CH3CN (v/v) containing 15%
NH4OH (m/v) and were vacuum-concentrated to *4 μl.
Mass-spectrometric analysis
Analysis of peptide mixtures was conducted using a QExactive HF-X mass spectrometer
(Thermo-Fisher Scientific, Palo Alto). Aliquots containing <1 μg of total peptide were chro-
matographed on a 50 cm column with 75 μm inner diameter packed C18 material. Peptide
separation occurred at 300 nl/min for 95 min using an acetonitrile gradient of 5–30%. The
temperature of the column oven was 55˚C. The mass spectrometer operated in data-dependent
mode with survey scans acquired at a resolution of 60,000. Up to the top 15 most abundant iso-
tope patterns with charge� +2 from the survey scan (300–1650 m/z) were selected with an iso-
lation window of 1.4 m/z and fragmented by HCD with normalized collision energies of 25.
The maximum ion injection times for the survey scan and the MS/MS scans were 20 and 28
ms, respectively. The ion target value for MS1 and MS2 scan modes was set to 3×106 and 105,
respectively. The dynamic exclusion was 30 s. The MS spectra were searched using MaxQuant
software. A maximum of two missed cleavages was allowed. The maximum false peptide and
protein discovery rate was specified as 0.01. The whole mass spectrometry analyses were per-
formed in three technical and two biological replicas per treatment.
Immunoblot and phospho-antibody immunoprecipitation analyses
Lysate protein samples were subjected to immunoblot and immunoprecipitation as previously
described [63]. Protein samples (40 μg) were boiled in sample buffer for 5 min, resolved by
7.5% sodium dodecyl sulfate polyacrylamide-gel electrophoresis and electrotransferred onto a
polyvinylidene difluoride membrane. Membranes were incubated for 30 min with TBST (Tris-
buffered saline, 0.05% Tween-20) containing 5% (w/v) skim milk. Blots were then washed six
times with TBST and incubated for 1 h at room temperature with secondary HRP-conjugated
antibodies diluted 5000-fold in 5% (w/v) skim milk in TBST. After repeating the washing
steps, signals were detected with enhanced chemiluminescence reagent. Immunoblots were
developed using ChemiDoc™ Imaging Systems (Bio-Rad, Feldkirchen). Figures were generated
using Photoshop/Illustrator (Adobe). Band densities of bands were measured with ImageJ.
Calculation of intensity ratios is based on (phospho-dimeric KCC2 + phospho-monomeric
KCC2) / (total dimeric KCC2 + total monomeric KCC2), (total dimeric KCC2 + total mono-
meric KCC2)/β-actin or tubulin, SPAK pThr233/SPAK, SPAK pSer373/SPAK, SPAK/β-actin or
tubulin, NKCC1 pThr203,207,212/NKCC1, NKCC1/β-actin or tubulin, as reported previously
[66]. Mann–Whitney U-test was used for comparison between 2 independent groups and Wil-
coxon matched pairs test was employed to compare paired data (GraphPad Prism 7.0, San
Diego, CA, USA).
For phospho-antibody immunoprecipitation, KCC isoforms were immunoprecipitated
from indicated cell extracts. 2 mg of the indicated clarified cell extract was mixed with 15 μg of
the indicated phospho-specific KCC antibody conjugated to 15 μl of protein-G–Sepharose, in
the added presence of 20 μg of the dephosphorylated form of the phosphopeptide antigen, and
incubated 2 hours at 4 ˚C with gentle shaking. Immunoprecipitates were washed three times
with 1 ml of lysis buffer containing 0.15 M NaCl and twice with 1 ml of buffer A. Bound pro-
teins were eluted with 1x LDS sample buffer.
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Antibodies
The following antibodies were purchased from Division of Signal Transduction Therapy
Unit at the University of Dundee: KCC2A phospho-Thr906 (SAYTYER(T)LMMEQRSRR
[residues 975–989 of human KCC3A] corresponding to SAYTYEK(T)LVMEQRSQI [resi-
dues 899–915 of human KCC2A], S959C); KCC2A phospho-Thr1007 (CYQEKVHM(T)
WTKDKYM [residues 1032–1046 of human KCC3A] corresponding to TDPEKVHL(T)
WTKDKSVA [residues 998–1014 of human KCC2A], S961C); SPAK/OSR1 (T-loop) phos-
pho-Thr233/Thr185 antibody (226–238 of human SPAK or residues 178–190 of human OSR1,
TRNKVRKpTFVGTP, S204C); SPAK/OSR1 (S-motif) phospho-Ser373/Ser325 antibody (367–
379 of human SPAK, RRVPGSpSGHLHKT, which is highly similar to residues 319–331 of
human OSR1 in which the sequence is RRVPGSpSGRLHKT, S670B); SPAK (427–443 of
human SPAK, QSLSVHDSQGPPVGTP, S849C); NKCC1 phospho-Thr203+Thr207+Thr212
(residues 198–217 of human NKCC1, HYYYDpTHTNpTYYLRpTFGHNT, S763B); NKCC1
phospho-Thr212/Thr217 (residues 208–223 of human NKCC1, YYLRpTFGHNpTMDAVPR,
S063D); NKCC1-total antibody (residues 1–260 of shark NKCC1, S841B). Pan-KCC2 anti-
body (residues 932–1043 of human KCC2) was from NeuroMab (73–013). KCC2 phospho-
Ser940 antibody was from ThermoFisher Scientific (PA5-95678). PKCδ phospho-Thr505
antibody (9374) and β-Actin (D6A8) antibody (12620) were from Cell Signaling Technology.
Anti (neuronal)-β-Tubulin III antibody was from Sigma-Aldrich (T8578). Secondary anti-
bodies coupled to horseradish peroxidase used for immunoblotting were obtained from
Pierce. IgG used in control immunoprecipitation experiments was affinity-purified from
pre-immune serum using Protein G-Sepharose.
Results
Dose-response analyses of staurosporine and NEM in stably transfected
HEKrnKCC2b cells
Staurosporine and NEM generally activate KCCs [40, 47, 86, 87]. To closer characterize their
mode of action, we used stably transfected HEKrnKCC2b cells, as high amount of the cotran-
sporter is advantageous for subsequent biochemical analyses. Immunoreactivity of
HEKrnKCC2b cells against KCC2 was detected in all cells with clear labeling at the cell mem-
brane and cytosol (Fig 1A). This is in agreement with previous cell surface expression analyses
that detected 11.8 ± 1.4% of total KCC2 in stably transfected rnKCC2b at the cell surface [79].
To quantify the impact of staurosporine and NEM on rnKCC2b transport activity, Tl+ flux
measurements were performed [79, 80, 88]. Transport activity in HEKrnKCC2b cells was 5.6
times higher compared to background (HEKrnKCC2b 100% ± 5.32%; mock; 17.7% ± 5.5%;
p = 4.3x10-5; n = 5) (Fig 1B). Here and elsewhere in the text, numbers indicate mean +/- SD, p
was determined using Wilcoxon-Mann-Whitney rank sum test. Treatment with 10 μM staur-
osporine or 1 mM NEM resulted in an approximately twofold increase of rnKCC2b activity
compared to untreated HEKrnKCC2b cells (staurosporine: 187.5% ± 37.1%, p = 3x10-3; NEM:
204% ± 23.2%; p = 3x10-3). The loop diuretics furosemide, that specifically inhibits the func-
tion of cation chloride cotransporters [89, 90], significantly inhibited the function of rnKCC2b
(34.7 ± 12.2%, p = 4 x10-5).
Next, we determined the dose-response relationships of staurosporine and NEM on
rnKCC2b transport activity by treating HEKrnKCC2b cells with different concentrations of
staurosporine (5–80 μM) or NEM (25–3,000 μM). Fig 2 represents the dose-response curve for
both agents. The dose-response curve for staurosporine (Fig 2A) was approximately a rectan-
gular hyperbola (n� 1, not significantly different from unity). This reflects Michaelis-Menten
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kinetics and suggests absence of cooperative effects. In contrast, the dose response curve for
NEM (Fig 2B) had a pronounced sigmoidal shape (n� 5), which reflects cooperative binding
kinetics. The effective dose ED50 (representing the potency) for staurosporine of stably trans-
fected HEKrnKCC2b was 12.8 ± 4.9 μM and the maximal efficacy (Emax) was 205 ± 40%. The
ED50 value for NEM was 0.5 ± 1.3 mM and Emax was 105 ± 6%. For further analyses, we used a
concentration of 8 μM staurosporine and 1 mM NEM, if not indicated otherwise as these con-
centrations significantly increase KCC2b transport activity.
Identification of CCC phosphorylation sites in stably transfected
HEKrnKCC2b cells by mass spectrometry analyses upon treatment with
staurosporine or NEM
Phosphoproteomics by mass spectrometry has the advantage of providing an unbiased survey
of phospho-sites. Therefore, we here used for the first time this technique to gain insight on
Fig 1. Staurosporine and NEM increase KCC2 activity. A: Immunoreactivity of stably transfected HEKrnKCC2b cells
was detected with labeling at the cell membrane and cytosol. Photomicrographs were taken with a confocal laser-
scanning microscope. Scale bar, 10 μm. B: Transport activity of rnKCC2b was determined by Tl+ flux measurements.
Treatment with 10 μM staurosporine or 1 mM NEM resulted in an approximately twofold increase of rnKCC2b
activity. Application of the loop diuretics furosemide (2 mM) significantly inhibited rnKCC2b function. The graph
represents the data of at least five independent measurements (each consisting of three technical replicates) normalized
to rnKCC2b. Statistical analyses: ���, p< 0.001 versus HEKrnKCC2b; Error bars represent SD.
https://doi.org/10.1371/journal.pone.0232967.g001
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the impact of staurosporine and NEM on rnKCC2b phospho-sites in HEKrnKCC2b. For each
condition, two biological and three technical replicas were performed. Phospho-sites detected
in at least one technical experiment are listed in Table 1. We first mapped KCC2b phospho-
sites in untreated HEKrnKCC2b cells. Twelve phospho-sites were identified: Ser25, Ser26, Ser31,
Thr32, Thr34 in the cytoplasmic N-terminus and Thr906, Ser937, Ser940, Thr1007, Ser1022, Ser1025,
and Ser1026 in the C-terminus (Table 1, untreated). These sites include all phospho-sites
already present in PhosphositePlus (Table 2) [91]. Recently phosphoproteomic data deposited
in Phosida and Phosphosite plus revealed that rat KCC2b tissue only harbors seven phospho-
sites (Table 2). Thus, we here report five phospho-sites (Ser25, Thr32, Thr906, Ser937 and
Thr1007) that were so far only reported for mouse but not rat KCC2 tissue (Table 2). These
sites most likely reflect different expression of kinases and phosphatases in different tissues
(HEK293 vs. rat brain tissue) [69] or increased detection rate in stably transfected HEKrnKCC2b
cells.
As KCC1, KCC4, and NKCC1 are endogenously expressed in HEK293 cells and as mass
spectrometric analysis provides data on most proteins in a given sample, we also investigated
phosphorylation sites of the following proteins: hsKCC1 (Thr893, analogous to rnKCC2b
Thr1007), hsKCC4 (Thr926 and Thr980, analogous to rnKCC2b Thr906 and Thr1007) and
hsNKCC1 (Thr212, Thr217, Ser242, Thr266, Thr268, Ser940, Tyr956, and Ser957). These phospho-
sites were already previously deposited in PhosphositePlus and Phosida (S1–S3 Tables). Over-
all, we detected only a low proportion of all so far deposited phospho-sites for these three
cotransporters. This might reflect low expression levels in HEK293 cells.
Next, we investigated the phosphorylation pattern of rnKCC2b upon staurosporine and
NEM treatment. Phosphorylation at Ser26, Thr32, Thr34, Thr906, Ser940, Thr1007, Ser1022, Ser1025,
Ser1026 of rnKCC2b were still present upon treatment with staurosporine or NEM, whereas
Fig 2. Dose-response relationship of staurosporine and NEM on KCC2 transport activity. HEKrnKCC2b cells were treated with
different concentrations of staurosporine (5–80 μM; A) or NEM (25–3,000 μM; B) for 15 min. Transport activity of rnKCC2b was
determined by Tl+ flux measurements. Treatment with staurosporine resulted in a classical Michaelis-Menden curve, whereas NEM
treatment showed a sigmoidal curve with a Hill coefficient of 5.2 ± 1.3 indicating a positive cooperative effect on rnKCC2b. The
graph represents the data of at least five independent measurements (each consisting of three technical replicates) normalized to
untreated HEKrnKCC2b.
https://doi.org/10.1371/journal.pone.0232967.g002
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phosphorylation of Ser25 and Ser937 was not detected anymore in either of the two conditions
(Table 1). Additionally, no phosphorylation was detected for Ser31 after treatment with
staurosporine.
Regarding endogenously expressed CCCs, the phospho-site Thr983 of hsKCC1 (analogous
to rnKCC2b Thr1007), Thr926 of hsKCC4 (analogous to rnKCC2b Thr906) and Thr212/217 and
Thr266/268 of hsNKCC1 could not be detected upon application of either of the two reagents.
Additionally, the phospho-sites Thr980 of hsKCC4 (analogous to rnKCC2b Thr906) and Ser242
of hsNKCC1 were not detected anymore after staurosporine treatment. The phospho-sites
Thr266, Ser940 and Tyr956/Ser957 of hsNKCC1 were still present upon treatment with stauros-
porine and NEM.
Several kinases were described to directly phosphorylate KCC2 and NKCC1. This includes
kinases of the WNK-SPAK/OSR1 and PKC mediated phosphorylation pathways. To gain fur-
ther insight into the regulatory phosphorylation mechanism, we explored their phosphoryla-
tion pattern as well. We detected several phosphorylation sites in hsWNK1, hsWNK2, and
hsSPAK [69, 93, 94] (Table 3). Upon all, we observed phosphorylation of the activating T-loop
residue Ser382 of hsWNK1 and the S-loop phosphorylation site of Ser372/373 of hsSPAK that is
phosphorylated by WNK1 [63, 69, 93]. Upon treatment with staurosporine or NEM, Ser382 of
hsWNK1 and Ser372/373 of hsSPAK were not detected anymore (Table 4). We were not able to
detect phosphorylation of Thr233 that is located in the T-loop kinase domain of hsSPAK. Nor-
mally, this site is directly phosphorylated by WNK1 and WNK4 to activate SPAK [60, 63, 69,
Table 1. Phospho-sites of stably transfected HEKrnKCC2b cells. Stably transfected HEKrnKCC2b were treated with or without 1 mM NEM or 8 μM staurosporine before
they were analyzed by mass spectrometry. The protein accession numbers are: hsNKCC1 (P55011), hsKCC1 (Q9UP95), rnKCC2b (Q9H2X9-2), hsKCC4 (Q9Y666).
Sample Phosphorylation sites Phosphopeptides untreated NEM treated staurosporine treated
hsNKCC1 T212; T217 TFGHNTMDAVPR (2)
S242 LLRPSLAELHDELEK (1) (1)
T266 EPFEDGFANGEESTPTR (3) (2) (2)
S940 EGLDISHLQGQEELLSSQEK (2) (2) (2) (1) (3) (1)
Y956; S957 DVVVSVEYSKK (3) (2) (3) (1) (3) (3)
hsKCC1 T983 IQMTWTRDK (2)
rnKCC2b S25; S26 ESSPFINSTDTEK (1)
S26 ESSPFINSTDTEK (2) (3) (3) (3) (3) (3)
S31 ESSPFINSTDTEK (2) (1)(1)
T32 ESSPFINSTDTEK (1) (1) (1)
T34 ESSPFINSTDTEK (3) (2) (2) (1)
T906 TLVMEQRSQILK (3) (3) (3)
S937 EIQSITDESRGSIR (2)
S940 EIQSITDESRGSIR (2) (3) (2) (1)
T1007 VHLTWTK (3) (3) (3)
S1022; S1025 GPSPVSSEGIK (3) (1) (3) (3) (1)
S1022; S1025; S1026 GPSPVSSEGIK (1) (1)
S1022; S1026 GPSPVSSEGIK (3) (3) (3)
S1026 GPSPVSSEGIK (3) (3) (3)
hsKCC4 T926 TLMMEQR (2)
T980 VQMTWTREK (3) (1)
The number in brackets indicates in how many technical replica a given phospho-site was detected (max. 3). Each bracket provides the results of one biological
experiment.
https://doi.org/10.1371/journal.pone.0232967.t001
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95]. Furthermore, we did not detect any phospho-sites of the ubiquitously expressed WNK3
and WNK4. Again, this probably results from low expression rates in HEK293 cells.
PKC mediates the phosphorylation of KCC2 and NKCC1 [48, 77, 96, 97]. The PKC family
consists of 10–12 isoforms grouped into three classes [98–101]. We detected several phospho-
sites in seven hsPKC family members (alpha, beta, delta, epsilon, theta, eta and iota; Table 4).
To summarize, according to mass spectrometry based phosphoproteome analyses, stauros-
porine and NEM reduce the number of detected phospho-sites of stably expressed rnKCC2b
and endogenously expressed hsKCC1, hsKCC4, hsNKCC1, hsWNK1 and hsSPAK. Phosphory-
lation of some sites (rnKCC2b: Ser31, hsNKCC1:Ser242, hsKCC4: Thr980) was absent only after
staurosporine treatment. Yet, these results can only be used as an indication since the absence
of phosphorylation sites can reflect detection problems caused by low phosphorylation rates.
Quantitative analyses of phospho-sites of rnKCC2b and hsNKCC1 upon
staurosporine and NEM treatment in HEKrnKCC2b cells
The experimental setup of our mass spectrometry-based analysis precluded quantification of
changes at individual phospho-sites. We therefore applied in a next step phospho-site-specific
antibody, as they were previously shown to quantitatively monitor changes in KCC2, NKCC1
and SPAK phosphorylation [23, 48, 59, 66, 70, 102]. Currently, a limited number of this class
Table 2. Phospho-sites in PhosphoSitePlus and PHOSIDA detected by mass spectrometry analyses.
Phosphosite Plus rnKCC2b Phosphosite Plus hsKCC2b Phosphosite Plus mmKCC2b Phosida mmKCC2b Transport activity measured by:
- - S25 S25 [47, 65]
S26 - S26 S26 [47, 65]
S31 S31 - S31 (40)
- - - (T32) -
T34 T34 T34 T34 [40, 92]
- Y594 - - -
- S599 - - -
- - - S649 -
- T798 - - -
- T808 - - -
- - T906 T906 [47, 61, 66]
- - S913 - -
- - S932 (S932) [40]
- - - (T934) [47]
- - S937 S937 [47]
S940 - S940 S940 [48, 77]
- - S988 - -
- - T999 - [40]
- - T1006 T1006 [47, 48, 61, 66]
- - - T1008 [40]
S1022 - S1021 S1021 [47]
S1025 - S1024 (S1024) [47]
S1026 - S1025 S1025 [47]
- - S1044 - -
Abbreviations used are as follows: rn, Rattus norvegicus; hs, Homo sapiens; mm, Mus musculus. Phospho-sites detected in the present mass spectrometry study are
marked in bold.
https://doi.org/10.1371/journal.pone.0232967.t002
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of antibodies is available for CCCs. They are directed against the well-known phospho-sites
Ser940, Thr906 and Thr1007 in rnKCC2b and Thr203, 207, 212 in hsNKCC1. So far, no data are
available for the staurosporine and NEM effect on Thr906 in rnKCC2b and Thr203, 207, 212 in
hsNKCC1 and the staurosporine effect on Ser940, and Thr1007 in rnKCC2b. To examine the
impact of staurosporine and NEM on the phosphorylation level of these sites, we treated
HEKrnKCC2 cells with 8 μM staurosporine, 1 mM NEM or DMSO as a vehicle control for 15
min. Lysates were probed for KCC2 or NKCC1 and phosphorylation levels of each phospho-
site were quantified (Fig 3). As previously described, positions Ser940, Thr906 and Thr1007 are
phosphorylated in KCC2b, and Thr203, 207, 212 in NKCC1 of untreated HEKrnKCC2 cells [48, 70,
102] (Fig 3). These data corroborate the phosphoproteome analyses which revealed phosphor-
ylation of Ser940, Thr906 and Thr1007 in KCC2b and Thr212/Thr217 in NKCC1 as well (Table 1).
Next, we observed the impact of staurosporine and NEM on these phospho-sites (Fig 3).
Both agents decreased the phosphorylation status of the WNK/SPAK sites Thr906 (p-value for
NEM or staurosporine: p = 0.0026) and Thr1007 (p-value for NEM or staurosporine:
p = 0.0026) of rnKCC2 and Thr203/207/212 of hsNKCC1 (p-value for NEM and staurosporine:
Table 3. Phospho-sites of hsSPAK, hsWNK1 and hsWNK2 endogenously expressed in stably transfected HEKrnKCC2b cells. Stably transfected HEKrnKCC2b were
treated with or without 1 mM NEM or 8 μM staurosporine before they were analyzed by mass spectrometry. The protein accession numbers are: hsSPAK (AAC72238.1),
hsWNK1 (Q9H4A3.2), hsWNK2 (Q9Y3S1.4).
sample Phosphorylation site Phosphopeptides untreated staurosporine treated NEM treated
hsSPAK 308 EMMKKYGK (2) (1) (1) (2)
354 LLTRTPDIAQRAK (1) (2) (1)
356 LLTRTPDIAQRAK (2) (2) (1)
403 AAFSQEK (3) (1) (1)
518; 520 ALKTLTFK (3) (2) (2) (3) (3) (3)
372; 373 VRRVPGSSGHLHK (1)
hsWNK1 11 QSSTPGSLFLSPPAPAPK (2) (1)
167; 170 DRPVSQPSLVGSK (3) (2) (3)
167; 174 DRPVSQPSLVGSK (3) (3) (2)
170 DRPVSQPSLVGSK (3) (2)
174 DRPVSQPSLVGSK (3) (3) (3) (3) (2) (3)
183 EEPPPARSGSGGGSAK (1) (1)
185 EEPPPARSGSGGGSAK (1)
183; 185 EEPPPARSGSGGGSAK (3) (3) (3)
382 SVIGTPEFMAPEMYEEK (1)
599 QQVEQSSASQTGIK (2) (3) (3) (3) (2)
1220 DDYGFSGSQK (2) (1)
1849 EGPVLATSSGAGVFK (3) (1)
1978 EGPVASPPFMDLEQAVLPAVIPK (3) (3) (3)
2121 VPPAVIIPPAAPLSGR (2) (1)
2245 GTFTDDLHK (1)
2372 SISNPPGSNLRTT (3) (3) (3) (3) (3)
hsWNK2 560 EQQDVGSPDK (2) (3) (3)
1889 AGSLGPETPSR (3) (3) (3)
1862 QASLPVSGSVAGDFVK (1) (3) (2) (1)
The number in brackets indicates in how many technical replica a given phospho-site was detected (max. 3). Each bracket provides the results of one biological
experiment.
https://doi.org/10.1371/journal.pone.0232967.t003
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p = 0.0026) [72–75, 103]. The reduced phosphorylation of Thr212 in hsNKCC1 agrees with our
phosphoproteome analyses as no phosphorylation of Thr212/Thr217 in NKCC1 was observed
(Table 1).
Previous analyses showed that SPAK directly phosphorylates Thr1007 of rnKCC2 [48] and
Thr203/207/212 of hsNKCC1 [70]. Treatment of HEK293 cells with NEM resulted in a decrease
of phosphorylation of Thr233 (p = 0,0026), that is located in the T-loop kinase domain, and the
S-loop phosphorylation site Ser373 of hsSPAK (p = 0.0026) (Fig 3). Both are targets of WNKs
[48, 69, 93]. As no data were available for the staurosporine mediated effect, we additionally
analyzed its impact on these phospho-sites in HEK293 cells. Staurosporine also reduced the
phosphorylation of Thr233 (p = 0.0026) and Ser373 (p = 0.0026) in hsSPAK (Fig 3). Thus, both
agents reduced phosphorylation levels of these SPAK phospho-sites. These data conform well
to our phosphoproteomic analyses, as no phosphorylated Ser372/373 of hsSPAK was detected
after treatment with either of the two agents.
Furthermore, staurosporine reduced phosphorylation of Ser940 (p = 0.0026) in HEKrnKCC2b,
whereas NEM increased phosphorylation of Ser940 (p = 0.046) significantly (Fig 3). Since,
Ser940 is directly phosphorylated by PKC [77, 104], we here analyzed the impact of both agents
on the T-loop phosphorylation site Thr505 of PKC-δ. Autophosphorylation of this site is most
probably essential for kinase activity [105–107]. Staurosporine significantly decreases Thr505
phosphorylation (p = 0.0026, Fig 3), whereas NEM slightly, but not significantly, increases
Thr505 phosphorylation (p = 0.064). The different impact of both agents on the phosphoryla-
tion of Thr505 of PKC correlates well with their impact on Ser940 phosphorylation of KCC2b.
We also determined whether staurosporine or NEM altered the total protein amount of
rnKCC2b, hsNKCC1 or hsSPAK (Fig 3). Whereas NEM resulted in increased KCC2 amount
(p = 0.0026), no obvious change was detected upon staurosporine treatment. NKCC1 and
SPAK levels were not changed significantly upon treatment with either agent.
To conclude, staurosporine and NEM reduced the phosphorylation status of SPAK (Thr233
and Ser373). This correlated with the reduction of the phosphorylation of Thr1007 in rnKCC2b
Table 4. Phospho-sites of hsPKC endogenously expressed in stably transfected HEKrnKCC2b cells. Stably transfected HEKrnKCC2b were treated with or without 1 mM
NEM or 8 μM staurosporine before they were analyzed by mass spectrometry. The protein accession numbers are: hsPKC Alpha (P17252), hsPKC Beta (P05771-2), hsPKC
Delta (Q05655), hsPKC Epsilon (Q02156), hsPKC Theta (Q04759), hsPKC Eta (P24723), and hsPKC Iota (P41743).
classes sample Phosphorylation site Phosphopeptides untreated staurosporine treated NEM treated
conventional PKC Alpha 10;11 ADVFPGNDSTASQDVANRFARK (3) (1)
10;13 ADVFPGNDSTASQDVANRFARK (3) (3) (1) (1) (1) (1)
226 TIRSTLNPQWNESFTFK (2) (2)
319 VISPSEDRK (3) (3) (3) (2) (2) (3)
PKC Beta 11 ADPAAGPPPSEGEESTVRFARK (2) (1) (2)
641 HPPVLTPPDQEVIR (3) (3) (3)
novel PKC Delta 645 ARLSYSDK (3) (3) (3)
647 ARLSYSDK (2) (1) (1)
664 NLIDSMDQSAFAGFSFVNPK (1) (3)
PKC Epsilon 309 VLADLGVTPDK (2) (2) (2)
PKC Theta 685 ALINSMDQNMFR (2) (1) (2)
PKC Eta 317 TLAGMGLQPGNISPTSK (3) (2) (2)
atypical PKC Iota 564 PNISGEFGLDNFDSQFTNEPVQLTPDDDDIVRK (3) (1) (3)
The number in brackets indicates in how many technical replica a given phospho-site was detected (max. 3). Each bracket provides the results of one biological
experiment.
https://doi.org/10.1371/journal.pone.0232967.t004
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Fig 3. Quantitative analyses of rnKCC2b and hsNKCC1 phospho-sites upon staurosporine and NEM treatment in HEKrnKCC2b
cells. Stably transfected HEKrnKCC2b cells were treated with DMSO (control), 8 μM staurosporine or 0.5 mM NEM, respectively, for 15
min. Cell lysates were harvested and subjected to immunoprecipitation (IP) and immunoblot (IB) with indicated antibodies. D, dimeric
KCC2; M, monomeric KCC2. Band intensities were quantified with ImageJ software. ���, p< 0.001; ��, p< 0.01; Wilcoxon-Mann-
Whitney test (n = 6).
https://doi.org/10.1371/journal.pone.0232967.g003
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and Thr203/207/212 in hsNKCC1. Additionally, both agents reduced phosphorylation of Thr906
in rnKCC2b, which is phosphorylated by WNKs and a yet unknown kinase [48]. Staurospor-
ine also reduced phosphorylation of the PKC site Ser940 in rnKCC2b, whereas NEM increased
its phosphorylation level. This correlated with the reduction of Thr505 phosphorylation of
PKC-δ upon staurosporine treatment and the impact of NEM to increase Thr505
phosphorylation.
Quantitative analyses of phospho-sites of KCC2 and NKCC1 upon
staurosporine or NEM treatment of rat immature hippocampal neurons
As KCC2 is predominantly expressed in neurons [20], we analyzed for the first time the impact
of staurosporine and NEM on the phosphorylation of specific phospho-sites of endogenously
expressed KCC2 and NKCC1 using immature (9 DIV) primary rat hippocampal neurons (Fig
4). At this age cultured hippocampal neurons exhibit prominent level of Thr906 and Thr1007
KCC2 phosphorylation [66] that could be a subject of modulation by staurosporine and NEM.
To this end, we treated neurons with 8 μM staurosporine, 0.5 mM NEM or DMSO as a vehicle
control for 15 min. NEM was reduced to 0.5 mM, since higher concentrations induced cell
death. As described for the analyses in stably transfected HEKrnKCC2b cells, we used phospho-
specific KCC2 and NKCC1 antibodies to quantify phosphorylation levels of each phospho-site
relatively to the DMSO control. In untreated cultured immature hippocampal neurons, Ser940,
Thr906 and Thr1007 in KCC2 and Thr203, 207, 212 in NKCC1 were phosphorylated, similar to sta-
bly transfected HEKrnKCC2b cells (Fig 4).
Most actions of staurosporine and NEM, as monitored by immunblots, were similar
between HEKrnKCC2b cells and immature hippocampal neurons. Both agents resulted in
decreased phosphorylation of Thr1007 in KCC2 (p-value for NEM and staurosporine:
p = 0.0026), Thr203/207/212 in NKCC1 (p-value for NEM and staurosporine: p = 0.0026), and
Ser373 in SPAK (p-value for NEM: p = 0.0026 and staurosporine: p = 0.0026). Additionally,
both agents reduced phosphorylation of the WNK-dependent phospho-site Thr906 in KCC2
(p-value for NEM and staurosporine: p = 0.0026). Finally, NEM increased the total protein
level of KCC2, as observed in HEK293 cells (p = 0.015) (Fig 4). We were not able to detect the
phosphorylation of Thr233 of SPAK using phospho-specific antibodies.
A marked difference, however, was observed for the PKC dependent phospho-site Ser940.
Here, treatment with NEM reduced phosphorylation of Ser940 (p = 0.0026) (Fig 4), contrary to
the results obtained in stably transfected HEKrnKCC2b cells (Fig 3). Treatment with staurospor-
ine also resulted in reduced phosphorylation of Ser940 (p = 0.0026), which was similar to its
action in HEKrnKCC2b cells. We could not detect Thr505 phosphorylation of PKC-δ due to low
expression rates.
To sum up, NEM affected the phosphorylation status of Ser940 in immature hippocampal
neurons (decrease) in the opposite way compared to HEKrnKCC2b cells (increase). All other
effects of staurosporine and NEM were similar between immature hippocampal neurons and
HEK293 cells, i.e. both reduced the phosphorylation status of Ser940, Thr906, and Thr1007 in
KCC2 and Thr203/207/212 in hsNKCC1.
Discussion
KCC2 and NKCC1 are key players for the development and maintenance of fast inhibitory
neurotransmission. Their oppositely directed transport of K+ and Cl- ions within the same
neuronal population necessitates a precisely coordinated regulatory mechanism for efficient
setting of the intracellular [Cl-] concentration [4, 38, 55–60] (Fig 5).
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Fig 4. Quantitative analyses of rnKCC2 and rnNKCC1 phospho-sites upon staurosporine or NEM treatment in immature hippocampal neurons.
Immature rat hippocampal neurons were treated with DMSO (control), 8 μM staurosporine or 0.5 mM NEM, respectively, for 15 min. Neuronal lysates
were harvested and subjected to immunoprecipitation (IP) and immunoblot (IB) with the indicated antibodies. D, dimeric KCC2; M, monomeric KCC2.
Band intensities were quantified using ImageJ software. ���, p< 0.001; ��, p< 0.01; Wilcoxon-Mann-Whitney test (n = 6).
https://doi.org/10.1371/journal.pone.0232967.g004
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Posttranslational regulation via the WNK-SPAK/OSR1 dependent phosphorylation repre-
sents a potent mechanism to regulate transport activity of KCC2 and NKCC1 in a reciprocal
way [60, 108–110] (Fig 5). Here, we show that staurosporine and NEM decrease phosphoryla-
tion of Thr233 and Ser373 in SPAK, of Thr1007 in rnKCC2 and Thr203, Thr207 and Thr212 in
hsNKCC1 in both HEK293 cells and immature cultured hippocampal neurons. Since SPAK
directly impairs phosphorylation of Thr1007 in rnKCC2 and Thr203, Thr207 and Thr212 in
hsNKCC1 [38, 48, 59, 60, 63, 68–76], our data suggest that staurosporine and NEM directly
affect the WNK-SPAK/OSR1 mediated phosphorylation of these residues in KCC2 and
NKCC1. The data are in line with previous analyses showing that NEM reduces phosphoryla-
tion of Ser373 in SPAK and Thr1007 in KCC2 using HEK293 cells and immature cortical neu-
rons [48]. Furthermore, application of staurosporine and NEM decreases phosphorylation of
Thr906 in rnKCC2. This site is directly phosphorylated by WNKs and a yet unknown kinase
[48]. However, functional in-depth analyses such as mutagenic approaches are required to
prove a causal relation between dephosphorylation of SPAK Thr233 and Ser373 and dephos-
phorylation of the specific KCC2 and NKCC1 phospho-sites upon staurosporine and NEM
treatment.
Recent analyses demonstrated that dephosphorylation of Thr906 and Thr1007 increases
KCC2 activity [61, 64–66], whereas dephosphorylation of Thr203, Thr207 and Thr212 decreases
NKCC1 activity [45, 51]. Furthermore, staurosporine and NEM results in activation of KCC2
(this study and [40, 47, 48, 59, 60, 79, 80], whereas they reduce NKCC1 activity [43–46, 51].
This suggests, that staurosporine and NEM mediated dephosphorylation of these phospho-
sites result in a reciprocal regulation of KCC2 (activation) and NKCC1 (inactivation) activity
most likely via the WNK/SPAK-dependent phosphorylation pathway. This is also in line with
the observation in immature hippocampal neurons that KCC2 can rapidly be activated by
staurosporine [42].
Fig 5. Staurosporine and NEM impair the WNK-SPAK/OSR1 mediated phosphorylation of KCC2 and NKCC1. In immature
hippocampal neurons, the WNK mediated phosphorylation of SPAK/OSR1 directly phosphorylates T1007 of KCC2 and T203, T207
and T212 of NKCC1. WNKs also interact with a yet unknown kinase to phosphorylate Thr906 of KCC2. Phosphorylation of these
residues decreases KCC2 and increases NKCC1 activity. Application of staurosporine or NEM decreases phosphorylation of S382 of
WNK1 and T233 and S373 of SPAK. This likely results in reduction of phosphorylation of T906 and T1007 in KCC2 and of T203, T207
and T212 in NKCC1. Dephosphorylation of these residues increases KCC2 activity and decreases NKCC1 activity. The figure is
modified from Moore et al. [39].
https://doi.org/10.1371/journal.pone.0232967.g005
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Another key regulatory KCC2 phospho-site is the PKC-mediated phosphorylation of
Ser940. Phosphorylation of Ser940 enhances KCC2 cell surface expression and increases ion
transport activity, whereas mutation of serine to alanine (mimicking the dephosphorylated
state) results in transport activity that is equal or decreased compared to wild-type KCC2
(KCC2wt) [65, 77, 111]. Our data demonstrate that staurosporine and NEM can differentially
affect Ser940 phosphorylation. Treatment of immature hippocampal neurons with either agent
results in decreased phosphorylation of Ser940. However, treatment of HEKrnKCC2b cells with
staurosporine decreases, whereas NEM increases phosphorylation of Ser940. This is in line with
the different effect of these agents on transport activity of the phosphomutants Ser31A/D,
Thr34A/D, Thr999A and Thr1008A/D [40].
Moreover, NEM has a cell-type specific impact on Ser940 phosphorylation. In immature
cortical neurons [48] and HEK293 cells, NEM increases Ser940 phosphorylation, whereas it
decreases Ser940 phosphorylation in immature cultured hippocampal neurons (Fig 4). The
mechanisms that cause this opposite effect of NEM on Ser940 phosphorylation in different tis-
sues is unclear. One possibility is that different NEM concentrations (HEK293 cells: 1 mM and
0.1 mM; immature hippocampal neurons: 0.5 mM; immature cortical neurons: 0.1 mM [48])
affect different regulatory pathways. Alternatively, tissues-specific sets of PKC isoforms and
phosphatases result in different phosphorylation patterns. Indeed, the PKC family consists of
10–12 isoforms grouped into three classes [98–101] that vary in their expression profile [112]
and regulation of their activity through several regulatory proteins, co-factors and second mes-
senger cascades [100, 101, 113]. This offers the opportunity to differentially regulate KCC2
function in distinct neuronal populations through PKC. In HEKrnKCC2b cells, we showed that
staurosporine reduced and NEM slightly increased phosphorylation of the T-loop phospho-
site Thr505 of PKC-δ. This correlated with decreased KCC2 Ser940 phosphorylation upon staur-
osporine treatment and increased phosphorylation of this residue upon NEM treatment. This
suggests, that both agents directly act on PKC-δ mediating the phosphorylation of Ser940 in
HEKrnKCC2b cells. However, more functional in-depth analyses are required to elucidate the
causal link between dephosphorylation of PKC-δ Thr505 and dephosphorylation of KCC2
Ser940 upon staurosporine treatment. Since we were unable to detect phosphorylation of PKC-
δ Thr505 in immature hippocampal neurons, we suggest that other PKC isoforms are involved
in the direct phosphorylation of KCC2 Ser940 in immature hippocampal neurons.
Our data furthermore reveal that staurosporine (HEKrnKCC2b cells, immature hippocampal
neurons) and NEM treatment (immature hippocampal neurons) decrease Ser940 phosphorylation
resulting in an equal or diminished transport activity compared to KCC2wt [65, 77, 111]. We
therefore conclude that Ser940 is not the key regulatory phospho-site mediating the staurosporine
and NEM-based stimulation effect on KCC2. This is in line with recent published analyses show-
ing that NEM still enhances the transport activity of Ser940A (mimicking dephosphorylated state),
indicating that other phospho-sites are important in NEM-dependent stimulation [40, 48].
NEM but not staurosporine increased total KCC2 amount in HEK293 cells and immature
cultured hippocampal neurons. In immature cortical neurons, Deep and coworkers [48]
detected the same trend of enhanced total KCC2 abundance (albeit not significant), resulting
in increased cell surface expression [48]. This suggests that in contrast to staurosporine, NEM
increases KCC2 expression and trafficking that could result in a higher KCC2 activity. The dif-
ferent impact of NEM on total KCC2 abundance in HEK293 in the study of Deep and cowork-
ers (no increase) and our analyses (increase) could result from different NEM concentration
used in the experiments (0.1 mM vs. 1 mM).
Via mass spectrometry analysis, we identified several new phosphorylation sites whose
function awaits further investigation. These sites are the N-terminal KCC2 phospho-site
Thr32, and the C-terminal NKCC1 phospho-sites Ser242, Thr266, Th268, Ser940, Tyr956 and
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Ser957. Future studies should investigate their regulatory impact on KCC2 and NKCC1
activity.
Conclusions
In conclusion, our data identify molecular mechanisms involved in staurosporine and NEM
mediated changes in transport activity of KCC2 and NKCC1, which are a defining feature of
CCCs [114]. The observation of cell-type specific action of these agents is in line with different
reversal potentials in mature neuronal populations [115] and calls for comprehensive neuron sub-
type-specific phospho analysis. The recently reported structural data of CCCs [116–119] finally
lay the foundation to analyze jointly the physiological role of phosphorylation and underlying
structural changes to obtain an integrative and mechanistic view of the action of phosphorylation.
Supporting information
S1 Table. Phospho-sites in PhosphoSitePlus detected by mass spectrometry analyses.
(DOCX)
S2 Table. Phospho-sites in PhosphoSitePlus detected by mass spectrometry analyses.
(DOCX)
S3 Table. Phospho-sites in PhosphoSitePlus detected by mass spectrometry analyses.
(DOCX)
S1 Fig. Quantitative analyses of rnKCC2 and hsNKCC1 phospho-sites upon staurosporine
and NEM treatment in HEKrnKCC2b cells.
(PDF)
S2 Fig. Quantitative analyses of rnKCC2 and hsNKCC1 phospho-sites upon staurosporine
and NEM treatment in immature hippocampal neurons.
(PDF)
Acknowledgments
We thank M. Reents for excellent technical support. Authors are also grateful to Prof. Matthias
Mann for continuous support and Katharina Zettl for technical support.
Author Contributions
Conceptualization: Igor Medina, Anna-Maria Hartmann.
Data curation: Jinwei Zhang, Antje Cordshagen, Igor Medina, Jacek R. Wisniewski, Michael
Winklhofer, Anna-Maria Hartmann.
Formal analysis: Jinwei Zhang, Antje Cordshagen, Jacek R. Wisniewski, Michael Winklhofer,
Anna-Maria Hartmann.
Funding acquisition: Hans Gerd Nothwang, Jacek R. Wisniewski, Anna-Maria Hartmann.
Investigation: Jinwei Zhang, Antje Cordshagen, Igor Medina, Jacek R. Wisniewski, Anna-
Maria Hartmann.
Methodology: Jinwei Zhang, Antje Cordshagen, Igor Medina, Jacek R. Wisniewski, Michael
Winklhofer, Anna-Maria Hartmann.
Project administration: Hans Gerd Nothwang, Anna-Maria Hartmann.
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 19 / 25
Supervision: Igor Medina, Hans Gerd Nothwang, Jacek R. Wisniewski, Anna-Maria
Hartmann.
Validation: Jinwei Zhang, Antje Cordshagen, Igor Medina, Jacek R. Wisniewski, Michael
Winklhofer, Anna-Maria Hartmann.
Visualization: Jinwei Zhang, Antje Cordshagen, Jacek R. Wisniewski, Michael Winklhofer,
Anna-Maria Hartmann.
Writing – original draft: Jinwei Zhang, Igor Medina, Hans Gerd Nothwang, Jacek R. Wis-
niewski, Michael Winklhofer, Anna-Maria Hartmann.
References
1. Hartmann A-M, Tesch D, Nothwang HG, Bininda-Emonds ORP. Evolution of the Cation Chloride
Cotransporter Family: Ancient Origins, Gene Losses, and Subfunctionalization through Duplication.
Molecular biology and evolution. 2014:mst225.
2. Gamba G. Molecular Physiology and Pathophysiology of electroneutral Cation-Chloride Cotransporter.
Physiological Reviews. 2005; 85:423–93. https://doi.org/10.1152/physrev.00011.2004 PMID: 15788703
3. Daigle ND, Carpentier GA, Frenette-Cotton R, Simard CF, Lefoll M-H, Noel M, et al. Molecular charac-
terization of a human cation-Cl- cotransporter (SLC12A8, CCC9A) that promotes polyamine and
amino acid transport. Journal of Cellular Physiology. 2009; 220:680–9. https://doi.org/10.1002/jcp.
21814 PMID: 19472210
4. Hartmann A, Nothwang HG. Molecular and evolutionary insights into the structural organization of cat-
ion chloride cotransporters. Name: Frontiers in Cellular Neuroscience. 2015; 8:470. https://doi.org/10.
3389/fncel.2014.00470 PMID: 25653592
5. Payne JA, Rivera C, Voipo J, Kaila K. Cation-Chloride cotransporters in neuronal communication,
development and trauma Trends in Neuroscience. 2003; 26:199–206.
6. Arroyo JP, Kahle KT, Gamba G. The SLC12 family of electroneutral cation-coupled chloride cotran-
sporters. Molecular Aspects of Medicine. 2013; 34:288–98. https://doi.org/10.1016/j.mam.2012.05.
002 PMID: 23506871
7. Kahle KT, Staley KJ, Nahed BV, Gamba G, Hebert SC, Lifton RP, et al. Roles of the cation-chloride
cotransporters in neurological disease. Nature Clinical Practice. 2008; 4:490–502.
8. Blaesse P, Airaksinen MS, Rivera C, Kaila K. Cation-Chloride Cotransporters and Neuronal Function.
Cell. 2009; 61:820–38.
9. Adragna NC, Fulvio MD, Lauf PK. Regulation of K-Cl Cotransport: from Function to Genes. Journal of
Membrane Biology. 2004; 201:109–37. https://doi.org/10.1007/s00232-004-0695-6 PMID: 15711773
10. Di Fulvio M, Alvarez-Leefmans FJ. The NKCC and NCC genes: an in silico view. Physiology and
Pathology of Chloride Transporters and Channels in the Nervous System. 2009:169–208.
11. Gagnon KB, Delpire E. Physiology of SLC12 transporters: lessons from inherited human genetic
mutations and genetically engineered mouse knockouts. American Journal of Physiology-Cell Physiol-
ogy. 2013; 304:C693–C714. https://doi.org/10.1152/ajpcell.00350.2012 PMID: 23325410
12. Medina I, Friedel P, Rivera C, Kahle KT, Kourdougli N, Uvarov P, et al. Current view on the functional
regulation of the neuronal K+-Cl− cotransporter KCC2. Frontiers in cellular neuroscience. 2014;8.
13. Achilles K, Okabe A, Ikeda M, Shimizu-Okabe C, Yamada F, Fukuda A, et al. Kinetic properties of Cl-
uptake mediated by Na+-dependent K+-2Cl- cotransport in immature rat neocortical neurons. Journal of
Neuroscience. 2007; 27:8616–27. https://doi.org/10.1523/JNEUROSCI.5041-06.2007 PMID: 17687039
14. Sipila¨ ST, Huttu K, Yamada J, Afzalov R, Voipio J, Blaesse P, et al. Compensatory enhancement of
intrinsic spiking upon NKCC1 disruption in neonatal hippocampus. The Journal of Neuroscience.
2009; 29:6982–8. https://doi.org/10.1523/JNEUROSCI.0443-09.2009 PMID: 19474325
15. Yamada J, Okabe M, Toyoda H, Kilb W, Luhmann HJ, Fukuda A. Cl- uptake promoting depolarizing
GABA actions in immature rat neocortical neurones is mediated by NKCC1. Journal of Physiology.
2004; 557:829–41. https://doi.org/10.1113/jphysiol.2004.062471 PMID: 15090604
16. Yuste R, Katz LC. Control of postsynaptic Ca2+ influx in developing neocortex by excitatory and inhibi-
tory neurotransmitters. Neuron. 1991; 6:333–44. https://doi.org/10.1016/0896-6273(91)90243-s
PMID: 1672071
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 20 / 25
17. Reichling DB, Kyrozis A, Wang J, MacDermott AB. Mechanism of GABA and glycine depolarization-
induced calcium transients in rat dorsal horn neurons. Journal of Physiology. 1994; 476:411–21.
https://doi.org/10.1113/jphysiol.1994.sp020142 PMID: 8057250
18. Owens DF, Boyce LH, Davis MBE, Kriegstein AR. Excitatory GABA responses in embryonic and neo-
natal cortical slices demonstrated by gramicidin perforated-patch recordings and calcium imaging.
The Journal of Neuroscience. 1996; 16:6416–23.
19. Hu¨bner CA, Stein V, Hermans-Borgmeyer I, Meyer T, Ballanyi K, Jentsch TJ. Disruption of KCC2
reveals an essential role of K-Cl cotransport already in early synaptic inhibition. Neuron. 2001;
30:515–24. https://doi.org/10.1016/s0896-6273(01)00297-5 PMID: 11395011
20. Uvarov P, Ludwig A, Markkanen M, Pruunsild P, Kaila K, Delpire E, et al. A novel N-termianl isoform of
the neuron-specific K-Cl Cotransporter KCC2. Journal of Biological Chemistry. 2007; 282(42):30570–
6. https://doi.org/10.1074/jbc.M705095200 PMID: 17715129
21. Kim JY, Liu CY, Zhang F, Duan X, Wen Z, Song J, et al. Interplay between DISC1 and GABA signaling
regulates neurogenesis in mice and risk for schizophrenia. Cell. 2012; 148(5):1051–64. https://doi.org/
10.1016/j.cell.2011.12.037 PMID: 22385968
22. Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S, et al. Oxytocin-mediated
GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science. 2014;
343(6171):675–9. https://doi.org/10.1126/science.1247190 PMID: 24503856
23. Kahle KT, Merner ND, Friedel P, Silayeva L, Liang B, Khanna A, et al. Genetically encoded impairment
of neuronal KCC2 cotransporter function in human idiopathic generalized epilepsy. EMBO reports.
2014; 15(7):766–74. https://doi.org/10.15252/embr.201438840 PMID: 24928908
24. Merner ND, Chandler MR, Bourassa C, Liang B, Khanna AR, Dion P, et al. Regulatory domain or
CpG site variation in SLC12A5, encoding the chloride transporter KCC2, in human autism and
schizophrenia. Frontiers in cellular neuroscience. 2015;9. https://doi.org/10.3389/fncel.2015.00009
PMID: 25698924
25. Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, et al. Perturbed chloride homeo-
stasis and GABAergic signaling in human temporal lobe epilepsy. The Journal of Neuroscience. 2007;
27(37):9866–73. https://doi.org/10.1523/JNEUROSCI.2761-07.2007 PMID: 17855601
26. Coull JAM, Boudreau D, Bachand K, Prescott SA, Nault F, Sik A, et al. Trans-synaptic shift in anion
gradient in spinal lamina I neurons as a mechanism of neuropathic pain. Nature. 2003; 424:938–42.
https://doi.org/10.1038/nature01868 PMID: 12931188
27. Rivera C, Li H, Thomas-Crussels J, Lahtinen H, Viitanen T, Nanobashvili A, et al. BDNF-induced TrkB
activation down-regulates the K+-Cl- cotransporter KCC2 and impairs neuronal Cl- extrusion. The
Journal of Cell Biology. 2002; 159(5):747–52. https://doi.org/10.1083/jcb.200209011 PMID: 12473684
28. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, et al. Down-regulation of the
potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nature medi-
cine. 2010; 16(3):302–7. https://doi.org/10.1038/nm.2107 PMID: 20190766
29. Papp E, Rivera C, Kaila K, Freund TF. Relationship between neuronal vulnerability and potassium-
chloride cotransporter 2 immunreactivity in hippocampus following transient forebrain ischemia. 2008.
2008;Neuroscience:677–89.
30. Shulga A, Thomas-Crusells J, Sigl T, Blaesse A, Mestres P, Meyer M, et al. Posttraumatic GABAA-
mediated [Ca2+] i increase is essential for the induction of brain-derived neurotrophic factor-depen-
dent survival of mature central neurons. The Journal of Neuroscience. 2008; 28(27):6996–7005.
https://doi.org/10.1523/JNEUROSCI.5268-07.2008 PMID: 18596173
31. Puskarjov M, Ahmad F, Khirug S, Sivakumaran S, Kaila K, Blaesse P. BDNF is required for seizure-
induced but not developmental up-regulation of KCC2 in the neonatal hippocampus. Neuropharmacol-
ogy. 2014.
32. Pisella LI, Gaiarsa J-L, Diabira D, Zhang J, Khalilov I, Duan J, et al. Impaired regulation of KCC2 phos-
phorylation leads to neuronal network dysfunction and neurodevelopmental pathology. 2019; 12(603):
eaay0300.
33. Delpire E, Lu J, England R, Dull C, Thorne T. Deafness and imbalance associated with inactivation of
the secretory Na-K-2Cl co-transporter. Nature Genetics. 1999; 22:192–5. https://doi.org/10.1038/
9713 PMID: 10369265
34. Delpire E, Mount DB. Human and Murine Phenotypes associated with defects in Cation-Chloride-
Cotransporter. Annu Rev Physiol. 2002; 64:803–43. https://doi.org/10.1146/annurev.physiol.64.
081501.155847 PMID: 11826289
35. Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, et al. NKCC1 transporter
facilates seizures in the developing brain. Nature Medicine. 2005; 11:1205–13. https://doi.org/10.
1038/nm1301 PMID: 16227993
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 21 / 25
36. Zhu L, Polley N, Mathews GC, Delpire E. NKCC1 and KCC2 prevent hyperexcitability in the mouse
hippocampus. Epilepsy research. 2008; 79(2–3):201–12. https://doi.org/10.1016/j.eplepsyres.2008.
02.005 PMID: 18394864
37. Ben-Ari Y. NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disor-
ders. Trends in neurosciences. 2017; 40(9):536–54. https://doi.org/10.1016/j.tins.2017.07.001 PMID:
28818303
38. Alessi DR, Zhang J, Khanna A, Hochdo¨rfer T, Shang Y, Kahle KT. The WNK-SPAK/OSR1 pathway:
Master regulator of cation-chloride cotransporters. Science signaling. 2014; 7(334):re3–re. https://doi.
org/10.1126/scisignal.2005365 PMID: 25028718
39. Moore YE, Kelley MR, Brandon NJ, Deeb TZ, Moss SJJTin. Seizing control of KCC2: a new therapeu-
tic target for epilepsy. 2017; 40(9):555–71.
40. Cordshagen A, Busch W, Winklhofer M, Nothwang HG, Hartmann A-M. Phosphoregulation of the intracel-
lular termini of K+-Cl− cotransporter 2 (KCC2) enables flexible control of its activity. Journal of Biological
Chemistry. 2018; 293(44):16984–93. https://doi.org/10.1074/jbc.RA118.004349 PMID: 30201606
41. Blaesse P, Guillemin I, Schindler J, Schweizer M, Delpire E, Khiroug L, et al. Oligomerization of KCC2
Correlates with Development of Inhibitory Neurotransmission. The Journal of Neuroscience. 2006; 26
(41):10407–19. https://doi.org/10.1523/JNEUROSCI.3257-06.2006 PMID: 17035525
42. Khirug S, Huttu K, Ludwig A, Smirnov S, Voipo J, Rivera C, et al. Distinct properties of functional KCC2
expression in immature mouse hippocampal neurons in culture and in acute slices. European Journal of
Neuroscience. 2005; 21(4):899–904. https://doi.org/10.1111/j.1460-9568.2005.03886.x PMID: 15787696
43. Flatman PW. Regulation of Na-K-2Cl cotranport by phosphorylation adn protein-protein interactions.
Biochemica et biophysica Acta. 2002; 1566:140–51.
44. Lytle C, McManus TJ, Haas M. A model of Na-K-2Cl cotransport based on ordered ion binding and
glide symmetry. American Journal of Physiology-Cell Physiology. 1998; 274(2):C299–C309.
45. Muzyamba M, Cossins A, Gibson J. Regulation of Na+-K+-2Cl− cotransport in turkey red cells: the
role of oxygen tension and protein phosphorylation. The Journal of physiology. 1999; 517(2):421–9.
46. Palfrey HC, Leung S. Inhibition of Na-K-2Cl cotransport and bumetanide binding by ethacrynic acid, its
analogues, and adducts. American Journal of Physiology-Cell Physiology. 1993; 264(5):C1270–C7.
47. Weber M, Hartmann A-M, Beyer T, Ripperger A, Nothwang HG. A novel regulatory locus of phosphor-
ylation in the C-terminus of the potassium chloride cotransporter KCC2 that interferes with N-ethylma-
leimide or staurosporine mediated activation. Journal of Biological Chemistry. 2014:jbc-M114.
48. Conway LC, Cardarelli RA, Moore YE, Jones K, McWilliams LJ, Baker DJ, et al. N-Ethylmaleimide
increases KCC2 cotransporter activity by modulating transporter phosphorylation. Journal of Biologi-
cal Chemistry. 2017; 292(52):21253–63. https://doi.org/10.1074/jbc.M117.817841 PMID: 29092909
49. Bize I, Gu¨venc¸ B, Buchbinder G, Brugnara C. Stimulation of human erythrocyte K-Cl cotransport and
protein phosphatase type 2A by n-ethylmaleimide: role of intracellular Mg++. The Journal of mem-
brane biology. 2000; 177(2):159–68. https://doi.org/10.1007/s002320001109 PMID: 11003690
50. Jennings ML, Schulz RK. Okadaic acid inhibition of KCl cotransport. Evidence that protein dephosphor-
ylation is necessary for activation of transport by either cell swelling or N-ethylmaleimide. The Journal of
general physiology. 1991; 97(4):799–817. https://doi.org/10.1085/jgp.97.4.799 PMID: 1647439
51. Gagnon KBE, England R, Delpire E. Characterization of SPAK and OSR1, regulatory kinases of the
Na-K-2Cl cotransporter. Molecular and cellular biology. 2006; 26(2):689–98. https://doi.org/10.1128/
MCB.26.2.689-698.2006 PMID: 16382158
52. Vardi N, Zhang L-L, Payne JA, Sterling P. Evidence that differnet cation chloride cotransporters in reti-
nal neurons allow opposite responses to GABA. The Journal of Neuroscience. 2000; 20(20):7657–63.
https://doi.org/10.1523/JNEUROSCI.20-20-07657.2000 PMID: 11027226
53. Balakrishnan V, Becker M, Lo¨hrke S, Nothwang HG, Gu¨resir E, Friauf E. Expression and Function of
Chloride Transportes during Development of Inhibitory Neurotransmission in the Auditory Brainstem.
The Journal of Neuroscience. 2003; 23:4134–45. https://doi.org/10.1523/JNEUROSCI.23-10-04134.
2003 PMID: 12764101
54. Price TJ, Trussel LO. Estimate of the chloride concentration in a central glutamatergic terminal: grami-
cidin perforated-patch study on the calyx of Held. Journal of Neuroscience. 2006; 26:11432–6. https://
doi.org/10.1523/JNEUROSCI.1660-06.2006 PMID: 17079672
55. Hartmann A-M, Blaesse P, Kranz T, Wenz M, Schindler J, Kaila K, et al. Opposite effect of membrane
raft perturbation on transport activity of KCC2 and NKCC1. Journal of Neurochemistry. 2009; 111
(2):321–31. https://doi.org/10.1111/j.1471-4159.2009.06343.x PMID: 19686239
56. Wenz M, Hartmann A-M, Friauf E, Nothwang HG. CIP1 is an activator of the K+-Cl- cotransporter
KCC2. Biochemical and Biophysical Research Communications. 2009; 381:388–92. https://doi.org/
10.1016/j.bbrc.2009.02.057 PMID: 19232517
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 22 / 25
57. Caron L, Rousseau F, Gagnon E´ , Isenring P. Cloning and functional characterization of a cation-chlo-
ride cotransporter-interacting protein. J Biol Chem. 2000; 275:32027–36. https://doi.org/10.1074/jbc.
M000108200 PMID: 10871601
58. De los Heros P, Kahle KT, Rinehart J, Bobadilla NA, Va´zquez N, San-Cristobal P, et al. WNK3
bypasses the tonicity requirement for K-Cl cotransporter activation via a phosphatase-dependent
pathway. PNAS. 2005; 103(6):1976–81.
59. Heubl M, Zhang J, Pressey JC, Al Awabdh S, Renner M, Gomez-Castro F, et al. GABA A receptor
dependent synaptic inhibition rapidly tunes KCC2 activity via the Cl−-sensitive WNK1 kinase. Nature
communications. 2017; 8(1):1776. https://doi.org/10.1038/s41467-017-01749-0 PMID: 29176664
60. Shekarabi M, Zhang J, Khanna AR, Ellison DH, Delpire E, Kahle KT. WNK kinase signaling in ion
homeostasis and human disease. Cell metabolism. 2017; 25(2):285–99. https://doi.org/10.1016/j.
cmet.2017.01.007 PMID: 28178566
61. Rinehart J, Maksimova YD, Tanis JE, Stone KL, Hodson CA, Zhang J, et al. Sites of Regulated Phos-
phorylation that Control K-Cl Cotransporter Activity. Cell. 2009; 138:525–36. https://doi.org/10.1016/j.
cell.2009.05.031 PMID: 19665974
62. Markkanen M, Ludwig A, Khirug S, Pryazhnikov E, Soni S, Khiroug L, et al. Implications of the N-termi-
nal heterogeneity for the neuronal K-Cl cotransporter KCC2 function. Brain research. 2017; 1675:87–
101. https://doi.org/10.1016/j.brainres.2017.08.034 PMID: 28888841
63. De los Heros P, Alessi DR, Gourlay R, Campbell DG, Deak M, Macartney TJ, et al. The WNK-regu-
lated SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-transporters. Biochem J.
2014; 458:559–73. https://doi.org/10.1042/BJ20131478 PMID: 24393035
64. Moore YE, Deeb TZ, Chadchankar H, Brandon NJ, Moss SJ. Potentiating KCC2 activity is sufficient to
limit the onset and severity of seizures. Proceedings of the National Academy of Sciences. 2018; 115
(40):10166–71.
65. Titz S, Sammler EM, Hormuzdi SG. Could tuning of the inhibitory tone involve graded changes in neu-
ronal chloride transport? Neuropharmacology. 2015.
66. Friedel P, Kahle KT, Zhang J, Hertz N, Pisella LI, Buhler E, et al. WNK1-regulated inhibitory phosphor-
ylation of the KCC2 cotransporter maintains the depolarizing action of GABA in immature neurons. Sci
Signal. 2015; 8(383):ra65–ra. https://doi.org/10.1126/scisignal.aaa0354 PMID: 26126716
67. Inoue K, Furukawa T, Kumada T, Yamada J, Wang T, Inoue R, et al. Taurine inhibits K+-Cl− cotran-
sporter KCC2 to regulate embryonic Cl− homeostasis via With-no-lysine (WNK) protein kinase signal-
ing pathway. Journal of Biological Chemistry. 2012; 287(25):20839–50. https://doi.org/10.1074/jbc.
M111.319418 PMID: 22544747
68. Hartmann A-M, Nothwang HG. Molecular and evolutionary insights into the structural organization of
cation chloride cotransporters. Frontiers in cellular neuroscience. 2014; 8.
69. Richardson C, Alessi DR. The regulation of salt transport and blood pressure by the WNK-SPAK/
OSR1 signalling pathway. Journal of cell science. 2008; 121(20):3293–304.
70. Thastrup JO, Rafiqi FH, Vitari AC, Pozo-Guisado E, Deak M, Mehellou Y, et al. SPAK/OSR1 regulate
NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autop-
hosphorylation. Biochemical Journal. 2012; 441(1):325–37. https://doi.org/10.1042/BJ20111879
PMID: 22032326
71. Geng Y, Hoke A, Delpire E. The Ste20 Kinases SPAK and OSR1 regulate NKCC1 function in sensory
neurons. The Journal of Biological Chemistry. 2009; 284:14020–8.
72. Gagnon KB, England R, Delpire E. A single binding motif is required for SPAK activation of the Na-K-
2Cl cotransporter. Cellular Physiology and Biochemistry. 2007; 20(1–4):131–42. https://doi.org/10.
1159/000104161 PMID: 17595523
73. Moriguchi T, Urushiyama S, Hisamoto N, Iemura S-I, Uchida S, Natsume T, et al. WNK1 regulates
phosphorylation of Cation-Chloride-coupled Cotransporters via the STE20-related kinases, SPAK and
OSR1. Journal of Biological Chemistry. 2005; 280(52):42685–93. https://doi.org/10.1074/jbc.
M510042200 PMID: 16263722
74. Vitari AC, Thastrup J, Rafiqi FH, Deak M, Morrice Na, Karlsson H, K., et al. Functional interactions of
the SPAK/OSR1 kinases with their upstream activator WNK1 and downstream substrate NKCC1. Bio-
chemical Journal 2006; 397:223–31. https://doi.org/10.1042/BJ20060220 PMID: 16669787
75. Darman RB, Forbush B. A regulatory locus of phosphorylation in the N terminus of the Na-K-Cl cotran-
sporter, NKCC1. Journal of Biological Chemistry. 2002; 277(40):37542–50. https://doi.org/10.1074/
jbc.M206293200 PMID: 12145304
76. Dowd BFX, Forbush B. PASK (Proline-Alanine-rich-related Kinase), a regulatory kinase of the Na-K-
Cl cotransporter (NKCC1). The Journal of Biological Chemistry. 2003; 278(30):27347–53. https://doi.
org/10.1074/jbc.M301899200 PMID: 12740379
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 23 / 25
77. Lee HHC, Walker JA, Jeffrey RW, Goodier RJ, Payne JA, Moss SJ. Direct PKC-dependent phosphoryla-
tion regulates the cell surface stability and activity of the potassium chloride cotransporter, KCC2. 2007.
78. Buerli T, Pellegrino C, Baer K, Lardi-Studler B, Chudotvorova I, Fritschy J-M, et al. Efficient transfec-
tion of DNA or shRNA vectors into neurons using magnetofection. Nature protocols. 2007; 2(12):3090.
https://doi.org/10.1038/nprot.2007.445 PMID: 18079708
79. Hartmann A-M, Pisella LI, Medina I, Nothwang HG. Molecular cloning and biochemical characteriza-
tion of two cation chloride cotransporter subfamily members of Hydra vulgaris. PloS one. 2017; 12(6):
e0179968. https://doi.org/10.1371/journal.pone.0179968 PMID: 28662098
80. Hartmann A-M, Wenz M, Mercado A, Sto¨rger C, Mount DB, Friauf E, et al. Differences in the large
extracellular loop between the K+-Cl- cotransporters KCC2 and KCC4. The Journal of Biological
Chemistry. 2010; 285(31):23994–4002. https://doi.org/10.1074/jbc.M110.144063 PMID: 20516068
81. Wisniewski JR. Quantitative Evaluation of Filter Aided Sample Preparation (FASP) and Multienzyme
Digestion FASP Protocols. Analytical chemistry. 2016; 88(10):5438–43. https://doi.org/10.1021/acs.
analchem.6b00859 PMID: 27119963
82. Wisniewski JR, Gaugaz FZ. Fast and sensitive total protein and Peptide assays for proteomic analy-
sis. Analytical chemistry. 2015; 87(8):4110–6. https://doi.org/10.1021/ac504689z PMID: 25837572
83. Wisniewski JR, Nagaraj N, Zougman A, Gnad F, Mann M. Brain phosphoproteome obtained by a
FASP-based method reveals plasma membrane protein topology. Journal of proteome research.
2010; 9(6):3280–9. https://doi.org/10.1021/pr1002214 PMID: 20415495
84. Wisniewski JR, Mann M. Consecutive proteolytic digestion in an enzyme reactor increases depth of
proteomic and phosphoproteomic analysis. Analytical chemistry. 2012; 84(6):2631–7. https://doi.org/
10.1021/ac300006b PMID: 22324799
85. Pinkse MW, Uitto PM, Hilhorst MJ, Ooms B, Heck AJ. Selective isolation at the femtomole level of phos-
phopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns.
Analytical chemistry. 2004; 76(14):3935–43. https://doi.org/10.1021/ac0498617 PMID: 15253627
86. Lytle C, McManus T. Coordinate modulation of Na-K-2Cl cotransport and K-Cl cotransport by cell vol-
ume and chloride. American Journal of Physiol Cell Physiology. 2002; 283:1422–31.
87. Gagnon E´ , England R, Delpire E. Volume sensitivity of cation-Cl- cotransporter is modulated by the
interaction of two kinases: Ste20-related proline-alanine-rich kinase and WNK4. American Journal of
Physiol Cell Physiol. 2005a; 290:134–42.
88. Delpire E, Days E, Lewis LM, Mi D, Kim K, Lindsley CW, et al. Small-molecule screen identifies inhibi-
tors of the neuronal K-Cl cotransporter KCC2. PNAS. 2009; 106(13):5383–8. https://doi.org/10.1073/
pnas.0812756106 PMID: 19279215
89. Gillen CM, Brill S, Payne JA, Forbush B. Molecular Cloning and Functional Expression of the K-Cl
Cotransporter from Rabbit, Rat and Human. The Journal of Biological Chemistry. 1996; 271:16237–44.
90. Culliford SJ, Ellory JC, Lang H-J, Englert H, Staines HM, Wilkins RJ. Specificity of classical and puta-
tive Cl-transport inhibitors on membrane transport pathways in human erythrocytes. Cellular Physiol-
ogy and Biochemistry. 2003; 13(4):181–8. https://doi.org/10.1159/000072420 PMID: 12876375
91. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: a
comprehensive resource for investigating the structure and function of experimentally determined
post-translational modifications in man and mouse. Nucleic acids research. 2011; 40(D1):D261–D70.
92. Bergeron MJ, Gagnon KBE, Caron L, Isenring P. Identification of Key functional domains in the C Ter-
minus of the K+-Cl- cotransporters. J Biol Chem. 2006; 281:15959–69. https://doi.org/10.1074/jbc.
M600015200 PMID: 16595678
93. Vitari AC, Deak M, Morrice NA, Alessi DR. The WNK1 and WNK4 protein kinases that are mutated in
Gordon’s hypertension syndrome phosphorylate and activate SPAK and OSR1 protein kinases. Bio-
chemical Journal. 2005; 391(1):17–24.
94. Zago´rska A, Pozo-Guisado E, Boudeau J, Vitari AC, Rafiqi FH, Thastrup J, et al. Regulation of activity
and localization of the WNK1 protein kinase by hyperosmotic stress. The Journal of cell biology. 2007;
176(1):89–100. https://doi.org/10.1083/jcb.200605093 PMID: 17190791
95. Uchida S, Sohara E, Rai T, Sasaki SJBotC. Regulation of with-no-lysine kinase signaling by Kelch-like
proteins. 2014; 106(2):45–56.
96. Smith L, Smallwood N, Altman A, Liedtke CM. PKCδ acts upstream of SPAK in the activation of
NKCC1 by hyperosmotic stress in human airway epithelial cells. Journal of Biological Chemistry.
2008; 283(32):22147–56. https://doi.org/10.1074/jbc.M801752200 PMID: 18550547
97. Del Castillo IC, Fedor-Chaiken M, Song JC, Starlinger V, Yoo J, Matlin KS, et al. Dynamic regulation
of Na+-K+-2Cl− cotransporter surface expression by PKC-ε in Cl−-secretory epithelia. American Jour-
nal of Physiology-Cell Physiology. 2005; 289(5):C1332–C43. https://doi.org/10.1152/ajpcell.00580.
2004 PMID: 16000638
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 24 / 25
98. Palmer R, Ridden J, Parker P. Identification of multiple, novel, protein kinase C-related gene products.
FEBS letters. 1994; 356(1):5–8. https://doi.org/10.1016/0014-5793(94)01202-4 PMID: 7988719
99. Webb BL, Hirst SJ, Giembycz MA. Protein kinase C isoenzymes: a review of their structure, regulation
and role in regulating airways smooth muscle tone and mitogenesis. British journal of pharmacology.
2000; 130(7):1433–52. https://doi.org/10.1038/sj.bjp.0703452 PMID: 10928943
100. Parker PJ, Murray-Rust J. PKC at a glance. Journal of cell science. 2004; 117(2):131–2.
101. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and
macromolecular interactions. Chemical reviews. 2001; 101(8):2353–64. https://doi.org/10.1021/
cr0002801 PMID: 11749377
102. Flemmer AW, Gimenz I, Dowd BFX, Darman RB, Forbush B. Activation of the Na-K-Cl cotransporter
NKCC1 detected with a Phospho-specific antibody. The Journal of Biological Chemistry. 2002; 277
(40):37551–8. https://doi.org/10.1074/jbc.M206294200 PMID: 12145305
103. Darman RB, Flemmer A, Forbush B. Modulation of ion transport by direct targeting of protein phospha-
tase type 1 tothe Na-K-Cl cotransporter. The Journal of Biological Chemistry. 2001; 276(37):34359–
62. https://doi.org/10.1074/jbc.C100368200 PMID: 11466303
104. Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJJNn. NMDA receptor activity downregulates KCC2
resulting in depolarizing GABA A receptor–mediated currents. 2011; 14(6):736.
105. Salzer E, Santos-Valente E, Keller B, Warnatz K, Boztug KJJoci. Protein kinase C δ: a gatekeeper of
immune homeostasis. 2016; 36(7):631–40.
106. Cheng N, He R, Tian J, Dinauer MC, Richard DYJTJoI. A critical role of protein kinase Cδ activation
loop phosphorylation in formyl-methionyl-leucyl-phenylalanine-induced phosphorylation of p47phox
and rapid activation of nicotinamide adenine dinucleotide phosphate oxidase. 2007; 179(11):7720–8.
107. Stempka L, Girod A, Mu¨ller H-J, Rincke G, Marks F, Gschwendt M, et al. Phosphorylation of Protein
Kinase Cδ (PKCδ) at Threonine 505 is not a prerequisite for enzymatic activity expression of rat pkcδ
and an alanine 505 mutant in bacteria in a functional form. 1997; 272(10):6805–11. https://doi.org/10.
1074/jbc.272.10.6805 PMID: 9045715
108. Kahle KT, Deeb TZ, Puskarjov M, Silayeva L, Liang B, Kaila K, et al. Modulation of neuronal activity by
phosphorylation of the K–Cl cotransporter KCC2. Trends in neurosciences. 2013; 36(12):726–37.
https://doi.org/10.1016/j.tins.2013.08.006 PMID: 24139641
109. Kahle KT, Delpire E. Kinase-KCC2 coupling: Cl− rheostasis, disease susceptibility, therapeutic target.
Journal of neurophysiology. 2015; 115(1):8–18. https://doi.org/10.1152/jn.00865.2015 PMID: 26510764
110. Kahle KT, Rinehart J, Lifton RP. Phosphoregulation of the Na–K–2Cl and K–Cl cotransporters by the
WNK kinases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2010; 1802
(12):1150–8.
111. Silayeva L, Deeb TZ, Hines RM, Kelley MR, Munoz MB, Lee HH, et al. KCC2 activity is critical in limit-
ing the onset and severity of status epilepticus. Proceedings of the National Academy of Sciences.
2015; 112(11):3523–8.
112. Naik MU, Benedikz E, Hernandez I, Libien J, Hrabe J, Valsamis M, et al. Distribution of protein kinase
Mζ and the complete protein kinase C isoform family in rat brain. Journal of Comparative Neurology.
2000; 426(2):243–58. https://doi.org/10.1002/1096-9861(20001016)426:2<243::aid-cne6>3.0.co;2-8
PMID: 10982466
113. Liu W, Heckman C. The sevenfold way of PKC regulation. Cellular signalling. 1998; 10(8):529–42.
https://doi.org/10.1016/s0898-6568(98)00012-6 PMID: 9794251
114. Lauf PK, Adragna NC. K-Cl cotransport; properties and molecular mechanism. Cellular Physiology
and Biochemistry. 2000; 10:341–54. https://doi.org/10.1159/000016357 PMID: 11125215
115. Yassin L, Radtke-Schuller S, Asraf H, Grothe B, Hershfinkel M, Forsythe ID, et al. Nitric oxide signaling
modulates synaptic inhibition in the superior paraolivary nucleus (SPN) via cGMP-dependent suppres-
sion of KCC2. 2014; 8:65.
116. Chew TA, Orlando BJ, Zhang J, Latorraca NR, Wang A, Hollingsworth SA, et al. Structure and mecha-
nism of the cation–chloride cotransporter NKCC1. 2019; 572(7770):488–92.
117. Liu S, Chang S, Han B, Xu L, Zhang M, Zhao C, et al. Cryo-EM structures of the human cation-chloride
cotransporter KCC1. 2019; 366(6464):505–8.
118. Delpire E, Guo JJAJoP-CP. Cryo-EM structures of Dr NKCC1 and hKCC1: a new milestone in the
physiology of cation-chloride cotransporters. 2020; 318(2):C225–C37.
119. Yang X, Wang Q, Cao EJNC. Structure of the human cation–chloride cotransporter NKCC1 deter-
mined by single-particle electron cryo-microscopy. 2020; 11(1):1–11.
PLOS ONE Staurosporine and NEM impair KCC2 and NKCC1 phosphorylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0232967 May 15, 2020 25 / 25
